10/632618

=> d his

(FILE 'CAPLUS' ENTERED AT 12:27:37 ON 27 FEB 2004)
DELETE HIS

FILE 'REGISTRY' ENTERED AT 13:09:55 ON 27 FEB 2004
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 14 S L1 SSS FULL
L4 13 S L3 NOT C32 H26 N2 O2/MF
L5 12 S L4 NOT C34 H31 N3 O4/MF
L6 11 S L5 NOT C35 H30 N2 O4 /MF

FILE 'CAPLUS' ENTERED AT 13:13:17 ON 27 FEB 2004
L7 4 S L6

FILE 'REGISTRY' ENTERED AT 13:44:38 ON 27 FEB 2004

FILE 'MARPAT' ENTERED AT 13:44:50 ON 27 FEB 2004
L8 0 S L3
L9 21 S L3 SSS FULL
L10 16 S L9/COMPLETE
L11 16 S L10 NOT L7
L12 0 S L11 AND NEURONAL

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> d l11 1-16 bib abs

L11 ANSWER 1 OF 16 MARPAT COPYRIGHT 2004 ACS on STN
AN 140:5203 MARPAT
TI Preparation of opioid and opioid-like compounds for therapeutic uses
IN Yen, Mao-Hsiung; Fan, Chin-Tsai
PA Jenken Bioscience, Inc., USA
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003097608	A2	20031127	WO 2003-US15461	20030516

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

10387318

PRAI US 2002-380841P 20020517
GI



I

AB (+)-Morphinan derivs., such as I [R = H, allyl, Ph, benzyl, alkyl, heteroarylalkyl, heterocyclyl, etc.], were prepared for therapeutic use in pharmaceutical compns. These morphinans are claimed for use in the treatment of neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, cognition deficit, memory loss, and stroke, cancers, such as skin cancer, small cell lung cancer, testicular cancer, esophageal cancer, breast cancer, endometrial cancer, ovarian cancer, central nervous system cancer, liver cancer, and prostate cancer, cardiac disorders, such as cardiac ischemia, congestive heart failure, and hypertension, as well as for the treatment of septic shock, inflammation, organ damage and neurol. disorders. Thus, (+)-3-methoxy-17-allylmorphinan hydrobromide was prepared in 63% yield via a an allylation reaction (+)-3-methoxymorphinan hydrochloride with allyl bromide using Et3N in THF followed by treatment of the base I (R = allyl) thus formed with HBr. Pharmacol. activities were determined by measurement of TNF-α, IL-10, nitrate, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase and creatinine levels.

L11 ANSWER 2 OF 16 MARPAT COPYRIGHT 2004 ACS on STN
AN 136:86056 MARPAT
TI Preparation of amino acid-N-carboxy anhydrides having substituent at nitrogen
IN Tsunoda, Hidetoshi; Sekiguchi, Michiru; Iizuka, Hajime; Sakai, Kazuya
PA Mitsui Chemicals, Inc., Japan
SO PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002538	A1	20020110	WO 2001-JP5780	20010704
	W: BR, CA, CN, IN, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	JP 2002201183	A2	20020716	JP 2001-203971	20010704
	EP 1298127	A1	20030402	EP 2001-949905	20010704
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	US 2002173664	A1	20021121	US 2002-70156	20020304
	US 6670447	B2	20031230		
PRAI	JP 2000-201745		20000704		
	JP 2000-303522		20001003		
	WO 2001-JP5780		20010704		

OS CASREACT 136:86056
GI



I

AB Amino acid-N-carboxy anhydrides having an N-acyl substituent at nitrogen which are represented by the following general formula [I; R1 = CH3, (CH3)2CH, (CH3)3C, C6H5CH2, C6H5CH2OCOCH2CH2; R2 = C6H5, CH3, CH3(CH2)8, C6H5CH2CH2] and a process for producing the same. These compds. easily react with free amino acids, alcs. or nucleophilic agents such as anions and serve as useful intermediates in producing amino acid derivs., optically active compds., peptides, polypeptides and the like, which are useful in various fields including medicines and pesticides, at a high yield. Moreover, a process for producing diamides R2CONHCHR1CONR3R4 (R1, R2 as above; R3 = H, alkyl, cycloalkyl, aryl) by using title compds. I with amine derivs. represented by R3NHR4. These diamides are also appropriately usable in producing amino acid derivs., optically active compds., peptides, polypeptides and the like.
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 16 MARPAT COPYRIGHT 2004 ACS on STN
AN 134:95517 MARPAT
TI Quinuclidine derivatives for the treatment of neurological disorders
IN Lauffer, David; Mullican, Michael
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002405	A1	20010111	WO 2000-US18355	20000705
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1200440	A1	20020502	EP 2000-945145	20000705
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003503500	T2	20030128	JP 2001-507841	20000705
	US 2002123507	A1	20020905	US 2002-39886	20020103
	US 6660748	B2	20031209		
	US 2004029912	A1	20040212	US 2003-632618	20030801
PRAI	US 1999-142509P	19990706			
	WO 2000-US18355	20000705			
	US 2002-39886	20020103			

AB Quinuclidine derivs. are provided for treating or preventing neuronal damage associated with neurol. diseases. The invention also provides compns. comprising the compds. of the invention and methods of using those compns. for treating or preventing neuronal damage.
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 16 MARPAT COPYRIGHT 2004 ACS on STN
AN 124:15483 MARPAT
TI Remedy for infectious diseases
IN Suzuki, Fujio
PA Tsumura and Co., Japan
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9525517	A1	19950928	WO 1995-JP491	19950317
	W: AU, CA, CN, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2185825	AA	19950928	CA 1995-2185825	19950317
	AU 9519605	A1	19951009	AU 1995-19605	19950317
	AU 689235	B2	19980326		
	EP 750908	A1	19970102	EP 1995-912470	19950317

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

	CN 1147766	A	19970416	CN 1995-192984	19950317
	US 5908857	A	19990601	US 1996-704673	19960918
	US 6030980	A	20000229	US 1998-135591	19980818
PRAI	JP 1994-72820	19940318			
	JP 1994-72821	19940318			
	WO 1995-JP491	19950317			

AB An infectious disease remedy comprises at least one member selected from the group consisting of Aconitum root alkaloids (e.g. benzoylmesaconine and 14-anisoylaconine), Aconitum roots and exts. thereof, gingerols and analogs thereof, and ginger rhizomes and products of treatment thereof. It has a remarkable effect of restoring the protective activity against infections and is useful for treating and preventing viral infection, fungal infection, and opportunistic infection. Benzoylmesaconine (10μg/kg/day) administered orally to cytomegalovirus-infected mice with exptl. burn effectively controlled the infection. Tablets were formulated containing corn starch 198.5, light anhydrous silicic acid 1, and 14-anisoylaconine 0.5 g.

L11 ANSWER 5 OF 16 MARPAT COPYRIGHT 2004 ACS on STN
AN 123:339729 MARPAT
TI Preparation of N-(carbamoylcyclohexyl)indole-3-carboxamides and analogs as tachykinin antagonists
IN Sisto, Alessandro; Fincham, Christopher; Potier, Edoardo; Manzini, Stefano; Arcamone, Federico; Lombardi, Paolo
PA A. Menarini Industrie Farmaceutiche Riunite S.R.L., Italy; Malesci Istituto Farmacobiologico S.P.A.
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9515311	A1	19950608	WO 1994-EP4012	19941202
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2177994	AA	19950608	CA 1994-2177994	19941202
	AU 9512731	A1	19950619	AU 1995-12731	19941202
	EP 731790	A1	19960918	EP 1995-903789	19941202
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 09506348	T2	19970624	JP 1994-515404	19941202
	US 5760248	A	19980602	US 1996-656068	19960531
PRAI	IT 1993-FI247	19931203			
	WO 1994-EP4012	19941202			

GI



I



II

AB Title compds. [I; A,B = N, CH; R1,R2 = H, OH, halo, Me(CH2CH2O)2, etc.; R3,R4,R8 = H, alkyl; R3R4 = (CH2)1-3; R5,Y = (hetero)aryl(alkyl), etc.; X = CO2R6, CH2OR6, NR7COR6, etc.; R6,R7 = groups cited for R5; Z = CH2, CO; dashed line = optional bond] were prepared Thus, aminocyclohexanecarboxylic acid II (R = OH) was amidated by (S)-H2NCH(CH2Ph)CO2CH2Ph to give II [R = (S)-NHCH(CH2Ph)CO2CH2Ph]. II [R = (R)-NHCHR5NMeCOCHMePh; R5 = 2-naphthylmethyl] had pKi of 8.7 for antagonism of substance P in vitro.

L11 ANSWER 6 OF 16 MARPAT COPYRIGHT 2004 ACS on STN
AN 122:284619 MARPAT

10387318

TI Preparation of substituted triazole and tetrazole derivatives as insecticides.
IN Dick, Michael R.
PA DowElanco, USA
SO U.S., 10 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5393767	A	19950228	US 1993-112498	19930826
WO 9608968	A1	19960328	WO 1994-US10703	19940921
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, UA, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9478003	A1	19960409	AU 1994-78003	19940921
PRAI US 1993-112498	19930826			
WO 1994-US10703	19940921			

GI



I



II

AB The title compds. I and II (Y = CH,N; Z = H,F,Cl,Br,CN,CONH2, alkoxycarbonyl, etc;R = N-containing heterocyclyl) are prepared as insecticides and acaricides, especially active against sucking insects, such as brown plant hoppers, and phytophagous mites, such as two-spotted spider mites. Exo-3-(5-aminotetrazol-2-yl)-1-azabicyclo[2.2.1]heptane is typical.

L11 ANSWER 7 OF 16 MARPAT COPYRIGHT 2004 ACS on STN
AN 122:133852 MARPAT
TI Preparation of peptide analog tachykinin antagonists.
IN Arcamone, Federico; Lombardi, Paolo; Manzini, Stefano; Potier, Edoardo; Sisto, Alessandro
PA A. Menarini Industrie Farmaceutiche Riunite S.R.L., Italy; Malesci Istituto Farmacobiologico S.P.A.
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9413694	A1	19940623	WO 1993-EP3387	19931202
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2151062	AA	19940623	CA 1993-2151062	19931202
AU 9456508	A1	19940704	AU 1994-56508	19931202
EP 672052	A1	19950920	EP 1994-901948	19931202
EP 672052	B1	19970716		
R: DE, ES, FR, GB				
ES 2105605	T3	19971016	ES 1994-901948	19931202
US 5641802	A	19970624	US 1995-448460	19950602
PRAI IT 1992-MI2779	19921204			
WO 1993-EP3387	19931202			

GI



I

AB Title compds. [I; Y = H, (substituted) alkyl, alkenyl, alkylnyl, cycloalkyl, etc.; R1, R2 = H, OH, halo; R1R2 = O; A, B = N, CH; R3, R4 = H, alkyl, alkenyl, alkynyl; R3R4 = (CH2)n; n = 1-3; R5 = alkyl, aryl, alkylaryl, arylalkyl; R6, R7 = H, alkyl, aryl, arylalkyl, alkylaryl; dotted line = optional double bond], were prepared Thus, Me trans-2-aminocyclohexanecarboxylate (preparation given) was coupled with indolin-3-carboxylic acid using hydroxybenzotriazole, 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide, and diisopropylethylamine in CH2Cl2 to give Me N-(indolin-3-ylcarbonyl)-trans-2-aminocyclohexanecarboxylate. This was saponified with aqueous NaOH and the product was condensed with phenylalanine N-methyl-N-benzylamide (preparation given) using bromotripyrrolidinephosphonium hexafluorophosphate and diisopropylethylamine in CH2Cl2 to give the N-methyl-N-benzylamide of Nα-[[N-(indolin-3-ylcarbonyl)(R,R)-trans-2-amino]cyclohexanoyl]phenylalanine and the corresponding diastereomer. I inhibited Substance P binding to guinea pig ileum by 95-100% at 1 μM.

L11 ANSWER 8 OF 16 MARPAT COPYRIGHT 2004 ACS on STN
AN 122:106537 MARPAT
TI Preparation of tetrazolyl peptide analogs as fibrinogen receptor antagonists
IN Nutt, Ruth F.; Veber, Daniel F.
PA Merck and Co., Inc., USA
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9409029	A1	19940428	WO 1993-US9569	19931005
	W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5340798	A	19940823	US 1992-961221	19921014
	AU 9453229	A1	19940509	AU 1994-53229	19931005
PRAI	US 1992-961221		19921014		
	WO 1993-US9569		19931005		

GI



I

AB AECH2CONHCHBCONHCHDD1 (A = primary, secondary, or tertiary amino group; B = carboxy or thiol group; D = H, alkyl, heteroalkyl, aryl, heteroaryl; D1 = 5-substituted tetrazolyl; E = nitrogen, carbocyclyl, heterocyclyl, carboaryl, heteroaryl group), were prepared as inhibitors of integrin protein complex function relating to cell attachment activity. Thus, title compound (I) (solution phase preparation given) inhibited platelet aggregation with IC50 = 0.011 nM.

L11 ANSWER 9 OF 16 MARPAT COPYRIGHT 2004 ACS on STN
AN 121:280563 MARPAT
TI Preparation of quinuclidine derivatives as cerebral function ameliorants
IN Fuse, Yoshihide; Yamamoto, Kozo; Kishida, Hideyuki; Miwa, Toshiaki; Hidaka, Takayoshi; Katsumi, Ikuo
PA Kanegafuchi Kagaku Kogyo Kabushiki Kaisha, Japan
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9419348	A1	19940901	WO 1994-JP218	19940214
	W: US				
	RW: CH, DE, FR, GB, IT				
	JP 06239861	A2	19940830	JP 1993-28281	19930217
	EP 638569	A1	19950215	EP 1994-906386	19940214
	R: CH, DE, FR, GB, IT, LI				
	US 5494917	A	19960227	US 1994-313118	19941012
PRAI	JP 1993-28281	19930217			
	WO 1994-JP218	19940214			

GI



I



II



III

AB The title compds. I [X = (CH2)a, etc.; a = 0 - 4; Y = (CH2)b, etc.; b = 0 - 3; Z = (CH2)c, etc.; c = 0 - 3; n = 1 - 5; R1 = H, (un)substituted Ph, etc.; R2 = H, alkyl, etc.] are prepared Quinuclidine derivs. II (cis) and III (trans) were prepared from 3-quinuclidinone and di-Et m-phenoxybenzylphosphonate. In in vitro tests for affinity for M1 and M2 receptors using (3H)-pirenzepine and (3H)-N-methylscopolamine, resp., III showed IC50 of 23±3 nM (M1 receptors) and IC50 of 4400±100 nM (M2 receptors). Formulations containing I are given.

L11 ANSWER 10 OF 16 MARPAT COPYRIGHT 2004 ACS on STN
AN 121:83070 MARPAT
TI Azabicyclic tachykinin receptor antagonists
IN Swain, Christopher John
PA Merck Sharp and Dohme Ltd., UK
SO Brit. UK Pat. Appl., 25 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2268931	A1	19940126	GB 1992-15527	19920722
PRAI	GB 1992-15527	19920722			

GI



I

10387318

AB Title compds. [I; O = residue of an azabicyclic ring system; R1 = (halo)phenyl, trifluoromethylphenyl; R2 = (substituted)phenyl; X = O, S, CH2, etc.; Y = H, OH, halo, etc.] are claimed as tachykinin receptor antagonists (no data). No prepared I are reported.

L11 ANSWER 11 OF 16 MARPAT COPYRIGHT 2004 ACS on STN
AN 119:243594 MARPAT
TI Preparation of substituted oxadiazole and thiadiazole compounds as acaricides and insecticides.
IN Dick, Michael R.; Chang, Chi Ping; Dripps, James E.; Wollowitz, Susan
PA DowElanco, USA
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9314636	A1	19930805	WO 1992-US10493	19921204
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	US 5244906	A	19930914	US 1992-824658	19920123
	CA 2105556	AA	19930724	CA 1992-2105556	19921204
	AU 9332396	A1	19930901	AU 1993-32396	19921204
	AU 651516	B2	19940721		
	EP 577788	A1	19940112	EP 1993-900881	19921204
	R: DE, ES, FR, GB, IT, NL				
	BR 9205804	A	19940517	BR 1992-5804	19921204
	JP 06509359	T2	19941020	JP 1992-513191	19921204
	CN 1097545	A	19950125	CN 1993-109067	19930723
PRAI	US 1992-824658	19920123			
	WO 1992-US10493	19921204			

GI



AB The title compds. I, II and III [Y = O, S; Z = H, F, Cl, Br, CONH2, CO2R1, OR1, SR1, NH2, (un)substituted Me or Et, etc.; R = N-containing heterocyclyl; R1 = Me or Et] are prepared as acaricides and insecticides. The cyclization of Me 1-azabicyclo[2,2,1]heptane-3-carboxylate with acetamide oxime, in the presence of NaOEt, gave 3-(3-methyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo[2,2,1]heptane (IV). IV gave >50% control of the 3rd instar green leafhopper (Nephotettix cincticeps), at >2 ppm, and of brown planthopper (Nilaparvata lugens) nymphs, at >0.5 ppm, in laboratory expts.

L11 ANSWER 12 OF 16 MARPAT COPYRIGHT 2004 ACS on STN
AN 119:139139 MARPAT
TI Azabicyclic compounds as tachykinin antagonists
IN Ladduwahetty, Tamara; Swain, Christopher J.
PA Merck Sharp and Dohme Ltd., UK
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 536817	A1	19930414	EP 1992-201931	19920627
	R: CH, DE, FR, GB, IT, LI, NL				
	CA 2072676	AA	19930106	CA 1992-2072676	19920629
	US 5256671	A	19931026	US 1992-905974	19920629
	JP 06157524	A2	19940603	JP 1992-178314	19920706
	JP 2614687	B2	19970528		
PRAI	GB 1991-14551	19910705			
	GB 1991-14887	19910710			
	GB 1992-4578	19920303			

GI



I



II

AB The azabicyclic compound I (Q = residue of an optionally substituted azabicyclic ring system; the dotted line represents an optional double bond; X = H, HO, =O, halo; R1 = H, Ph, thienyl which may be substituted by halo or F3C; R2 = Ph, thienyl, benzyl which may be substituted by halo or F3C; R3, R4, R5, = H, C1-6 alkyl, C2-6 alkynyl, C2-6 alkenyl, halo, cyano, alkoxy, alkylthio amino, etc. were prepared as tachykinin antagonists. Thus, 2-(diphenylmethyl)quinuclidin-3-one was treated with diisopropyl cyanomethylphosphonate followed by reduction with DIBAL-H to give E-3-(formylmethylene)-2-benzhydrylquinuclidine, which underwent Grignard reaction with bromoanisole to give the E-3-[(2-methoxyphenyl)-2-hydroxyethylidene]-2-benzylhydrylquinuclidine II and its stereoisomer. The tachykinin antagonist 1C90 of II was 50 ηM.

L11 ANSWER 13 OF 16 MARPAT COPYRIGHT 2004 ACS on STN
AN 118:80807 MARPAT
TI Preparation of benzyloxyazabicycloalkanes as tachykinin antagonists
IN Baker, Raymond; Swain, Christopher; Seward, Eileen M.
PA Merck Sharp and Dohme Ltd., UK
SO Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 499313	A1	19920819	EP 1992-200303	19920204
	EP 499313	B1	19970611		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE				
	US 5242930	A	19930907	US 1992-830822	19920204
	AT 154354	E	19970615	AT 1992-200303	19920204
	CA 2060949	AA	19920812	CA 1992-2060949	19920210
	JP 05078354	A2	19930330	JP 1992-25068	19920212
	JP 2500279	B2	19960529		
PRAI	GB 1991-2809		19910211		
	GB 1991-7403		19910409		
	GB 1991-13892		19910627		
	GB 1991-14553		19910705		

GI



I



@ oxalate II

AB Title compds. [I; Q = azabicyclic ring residue X = O, S; Y = H, OH; R1, R2 = (halo- or CF3-substituted) Ph, thienyl; R3-R5 = H, alkyl, alkenyl, alkynyl, halo, cyano, NO2, CF3, Me3Si, OR6, SMe, SOMe, SO2Me, NR6R7, NR6COR7, NR6CO2R7, CO2R6, CONR6R7; R6, R7 = H, alkyl, Ph, CF3], were

prepared Thus, cis-2-diphenylmethyl-1-azabicyclo[2.2.2]octane-3-ol (preparation by reduction of the corresponding ketone given) in dimethoxyethane at 0° was treated with 18-crown-6, KN(SiMe3)2 in PhMe, and 3-O2NC6H4CH2Br in dimethoxyethane. The mixture was stirred 1 h to give 50% coupling product, which was converted to the title compound II. II at 1.0 μM gave > 10% inhibition of substance P Me ester-induced contraction of guinea pig ileum longitudinal muscle.

L11 ANSWER 14 OF 16 MARPAT COPYRIGHT 2004 ACS on STN
AN 117:198529 MARPAT
TI Ophthalmic pharmaceuticals containing substituted pyridine derivatives for treatment of glaucoma
IN Lotti, Victor; Showell, Graham A.
PA Merck Sharp and Dohme Ltd., UK
SO Can. Pat. Appl., 25 pp.
CODEN: CPXXEB
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2058249	AA	19911208	CA 1991-2058249	19911220
	EP 492902	A1	19920701	EP 1991-311528	19911211
	R: CH, DE, FR, GB, IT, LI, NL				
	JP 05140158	A2	19930608	JP 1991-361151	19911220
PRAI	GB 1990-27824	19901221			
	GB 1991-12307	19910607			

AB Pyridine derivs., substituted on the pyridine nucleus by a nonarom. azabicyclic ring system with >5 ring atom are used in ophthalmic pharmaceuticals for treatment of glaucoma. Thus, 0.05% 3-[2-(6-ethoxypyridin)yl-1-azabicyclo[2,2,2]octane hydrogen oxalate (I) changed intraocular pressure by 3.0 mmHg. An eye drop contained I 0.5, benzalkonium chloride 0.02%, Na2EDTA 0.05, NaCl 0.8, and water to 100%.

L11 ANSWER 15 OF 16 MARPAT COPYRIGHT 2004 ACS on STN
AN 113:152263 MARPAT
TI Preparation of 1-azabicycloalkanes as cholinergics
IN Galliani, Giulio; Barzaghi, Fernando; Bonetti, Carla; Toja, Emilio
PA Roussel-UCLAF, Fr.
SO Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 366561	A2	19900502	EP 1989-402973	19891027
	EP 366561	A3	19910918		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 02178280	A2	19900711	JP 1989-277350	19891026
	US 5015655	A	19910514	US 1989-426778	19891026
	CA 2001686	AA	19900428	CA 1989-2001686	19891027
	US 5183893	A	19930202	US 1991-664120	19910326
PRAI	IT 1988-22452	19881028			
	US 1989-426778	19891026			

GI



AB The title compds. [I; R1, R2 = H, alkyl, alkenyl, etc.] were prepared Hydrolysis-oxidation of (methoxymethylene)quinuclidine II in CHCl3 with HClO4 gave 3-quinuclidinecarboxaldehyde (III, Z = O), which was condensed with

H2NOMe.HCl to give III (Z = NOMe) (IV). IV at 1.10-3 at 1.10-3 and 1.10-8M showed muscarinic and nicotinic effects on guinea pig ileum. Tablets and gelatin capsules containing I were formulated.

L11 ANSWER 16 OF 16 MARPAT COPYRIGHT 2004 ACS on STN
AN 111:153786 MARPAT
TI Preparation of nonaromatic azacyclic or azabicyclic ring-containing 1,3-oxazoles or 1,3-thiazoles for the treatment of senile dementia
IN Baker, Raymond; Snow, Roger J.; Saunders, John; Showell, Graham A.
PA Merck Sharp and Dohme Ltd., UK
SO Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 307141	A2	19890315	EP 1988-308126	19880901
	EP 307141	A3	19890412		
	EP 307141	B1	19930113		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SE				
	AT 84415	E	19930115	AT 1988-308126	19880901
	ES 2053748	T3	19940801	ES 1988-308126	19880901
	DK 8805032	A	19890428	DK 1988-5032	19880909
	JP 01151576	A2	19890614	JP 1988-225568	19880910
	US 5324723	A	19940628	US 1993-86389	19930701
PRAI	GB 1987-21343		19870910		
	GB 1988-1759		19880127		
	EP 1988-308126		19880901		
	US 1988-239892		19880902		
	US 1990-454492		19900205		
	US 1992-912469		19920713		

GI For diagram(s), see printed CA Issue.
AB The title compds. [I; X = O, S; R1 = nonarom. azacyclic or azabicyclo ring; R2 = H, halo, CF3, OH, alkoxy, cyano, (substituted) amino, hydrazino, etc.] useful for treating mental illness (e.g. senile dementia) and as analgesics, were prepared Saponification of 3-methoxycarbonylquinuclidine with LiOH.H2O in refluxing MeOH and methylation of the resulting 3-carboxyquinuclidine Li salt with MeLi in THF gave 3-acetylquinuclidine which was heated 6 h with iodine and H2NCSNH2 on a steam bath to give 3-(2-amino-1,3-thiazol-4-yl)quinuclidine. Treatment of this in 50% hypophosphorus acid with aqueous NaNO2 for 5 days gave 3-(1,3-thiazol-4-yl)quinuclidine (II). Tablets containing II.hydrogen oxalate 25.0, microcryst. cellulose 37.25, modified food corn starch 37.25, and Mg stearate 0.50 mg were formulated..

=>

10387318

=> d his

(FILE 'CAPLUS' ENTERED AT 12:27:37 ON 27 FEB 2004)
DELETE HIS

FILE 'REGISTRY' ENTERED AT 13:09:55 ON 27 FEB 2004
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 14 S L1 SSS FULL
L4 13 S L3 NOT C32 H26 N2 O2/MF
L5 12 S L4 NOT C34 H31 N3 O4/MF
L6 11 S L5 NOT C35 H30 N2 O4 /MF

FILE 'CAPLUS' ENTERED AT 13:13:17 ON 27 FEB 2004
L7 4 S L6

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> d 1-4 bib abs hitstr

L7 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:41475 CAPLUS
DN 140:111404
TI Preparation of N-aryl diazaspirocyclic compounds as nicotinic cholinergic receptor modulators for treating nervous system and other disorders
IN Bhatti, Balwinder S.; Miller, Craig H.; Schmidt, Jeffrey D.
PA Targacept, Inc., USA
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004005293	A2	20040115	WO 2003-US20524	20030627

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-394337P P 20020705
GI



I



II



III

AB Compds., pharmaceutical compns. including the compds., and methods of preparation and use thereof are disclosed. The compds. are N-aryl diazaspirocyclic compds. (shown as I and II; variables defined below; e.g. III), bridged analogs of N-heteroaryl diazaspirocyclic compds., or prodrugs or metabolites of these compds. The aryl group can be a five or six-membered heterocyclic ring (heteroaryl). The compds. and compns. can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which were characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compds. and compns. can also be used to alleviate pain. The compds. can alter the number of nicotinic cholinergic receptors of the brain of the patient, exhibit neuroprotective effects and when employed in effective amts., not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant neg. effects upon the gastrointestinal tract, and significant effects upon skeletal muscle). For the α4β2 subtype, the Ki value for each of the examples of I was <1 μM, indicating that I bind tightly to the receptor. Although the methods of preparation are not claimed, 13 example prepns. are included. For example, III was prepared in 5 steps (76, 93, 96, 66 and 88 % yields, resp.) starting from Et (S)-N-benzylpyrrolidine-2-carboxylate and nitroethylene and involving intermediates Et 2-(2-nitroethyl)-1-benzylpyrrolidine-2-carboxylate, 6-benzyl-2,6-diazaspiro[4.4]nonan-1-one, 1-benzyl-1,7-diazaspiro[4.4]nonane and 1-benzyl-7-(3-pyridyl)-1,7-diazaspiro[4.4]nonane. For I: Q1 is (CZ2)u; QII is (CZ2)v; QIII is (CZ2)w; and QIV is (CZ2)x; u, v, w and x are individually 0-4, preferably 0-3; R is H, lower alkyl, acyl, alkoxycarbonyl or aryloxycarbonyl; Z is H and (un)substituted alkyl, cycloalkyl, heterocyclyl, aryl, alkylaryl, arylalkyl; Cy is a six membered ring linked via C to the N of the rest of I and each of the remaining ring atoms = N, N bonded to O or C bonded to a substituent species, wherein ≤3 are N or N bonded to O, or Cy is a five 5-membered heteroarom. ring linked via C to the N of the rest of I; addnl. details are given in the claims. For II: QV = (CZ2)y; QVI = (CZ2)z; y and z = 0-4; the bridged diazaspirocyclic ring contains 8-13 members; the rest of the variables are defined similarly to those for I.

IT **646055-79-0P**, Ethyl 1-azabicyclo[2.2.1]heptane-2-carboxylate
646055-80-3P, Ethyl 1-aza-2-(2-nitroethyl)bicyclo[2.2.1]heptane-2-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-aryl diazaspirocyclic compds. as nicotinic cholinergic receptor modulators for treating nervous system and other disorders)

RN 646055-79-0 CAPLUS

CN 1-Azabicyclo[2.2.1]heptane-2-carboxylic acid, ethyl ester (9CI) (CA INDEX NAME)



RN 646055-80-3 CAPLUS
CN 1-Azabicyclo[2.2.1]heptane-2-carboxylic acid, 2-(2-nitroethyl)-, ethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:6240 CAPLUS
DN 114:6240
TI Synthesis of acyclic and heterocyclic derivatives of 2-carboxyquinuclidine. IV
AU Bulacinski, Andrzej Benedykt
CS Dep. Technol. Pharm. Prod., Sch. Med., Warsaw, 02-097, Pol.
SO Acta Poloniae Pharmaceutica (1989), 46(5-6), 429-34
CODEN: APPHAX; ISSN: 0001-6837
DT Journal
LA Polish
GI



I



II

AB Quinuclidine derivs. I (n = 1, R1 = H, R2 = 2- and 4-MeO and 2-, 3-, and 4-Cl; n = 2, R1 = 3-MeO, R2 = 4-MeO; R1 = H, R2 = 4-Cl) were prepared in 47-72% yields by treating 2-chlorocarbonylquinuclidine.HCl with the appropriately substituted phenethylamine and benzylamine, resp., in C6H6 in presence of Et3N. Phenylalkylaminomethylquinuclidines II (n = 1, R1 = H, R2 = 2- and 4-MeO; n = 2, R1 = 3-MeO, R2 = 4-MeO) were obtained by reduction of the corresponding I with LiAlH4 in Et2O-THF.
IT **130877-60-0P 130877-61-1P 130877-65-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
RN 130877-60-0 CAPLUS
CN 1-Azabicyclo[2.2.1]heptane-2-carboxamide, N-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 130877-61-1 CAPLUS
CN 1-Azabicyclo[2.2.1]heptane-2-carboxamide, N-[(4-methoxyphenyl)methyl]-
(9CI) (CA INDEX NAME)



RN 130877-65-5 CAPLUS
CN 1-Azabicyclo[2.2.1]heptane-2-carboxamide, N-[2-(3,4-dimethoxyphenyl)ethyl]-
(9CI) (CA INDEX NAME)



IT **130877-62-2P 130877-63-3P 130877-64-4P**
130877-66-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 130877-62-2 CAPLUS
CN 1-Azabicyclo[2.2.1]heptane-2-carboxamide, N-[(2-chlorophenyl)methyl]-
(9CI) (CA INDEX NAME)



RN 130877-63-3 CAPLUS
CN 1-Azabicyclo[2.2.1]heptane-2-carboxamide, N-[(3-chlorophenyl)methyl]-
(9CI) (CA INDEX NAME)



RN 130877-64-4 CAPLUS
CN 1-Azabicyclo[2.2.1]heptane-2-carboxamide, N-[(4-chlorophenyl)methyl]-
(9CI) (CA INDEX NAME)

10387318



RN 130877-66-6 CAPLUS
CN 1-Azabicyclo[2.2.1]heptane-2-carboxamide, N-[2-(4-chlorophenyl)ethyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1984:22615 CAPLUS
DN 100:22615
TI Double cycloaddition reaction of imidazolium methylides. Intermolecular 1,3-dipolar and intramolecular Diels-Alder cycloaddition reactions
AU Tsuge, Otohiko; Kanemasa, Shuji; Takenaka, Shigeori
CS Interdiscip. Grad. Sch. Eng. Sci., Kyushu Univ., Kasuga, 816, Japan
SO Bulletin of the Chemical Society of Japan (1983), 56(7), 2073-6
CODEN: BCSJA8; ISSN: 0009-2673
DT Journal
LA English
GI



I

AB Imidazolium methylides such as imidazolium dicyanomethylide and bis(ethoxycarbonyl)methylide react with the methylenecyclopropenes with unsatd. substituents at the 4-position in the fashion of double cycloaddn. reaction, leading to the novel cage compds., e.g. I, which involves an intermol. 1,3-dipolar cycloaddn. reaction and an intramol. Diels-Alder reaction.
IT **87446-61-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 87446-61-5 CAPLUS
CN 2,4,4a-Metheno-4aH-7-oxa-1,2a-diazacyclopent[cd]indene-3,3(4H)-dicarboxylic acid, 5-cyano-1,2,7a,7b-tetrahydro-1-methyl-4,6,8-triphenyl-, diethyl ester (9CI) (CA INDEX NAME)

10387318



L7 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1983:453635 CAPLUS
DN 99:53635
TI Double cycloaddition reaction of pyridinium N-methylides to methylenecyclopropenes leading to cage compounds
AU Tsuge, Otohiko; Kanemasa, Shuji; Takenaka, Shigeori
CS Interdisc. Grad. Sch. Eng. Sci., Kyushu Univ., Kasuga, 816, Japan
SO Chemistry Letters (1983), (4), 519-22
CODEN: CMLTAG; ISSN: 0366-7022
DT Journal
LA English
GI



I II III IV

AB Cage compds. (I, II, R = R1 = CN, CO2Et; R = H, R1 = CO2Me, CO2Et, Bz) were prepared in 16-89% yields by the title reaction of III with IV (R2 = Ph, Bz).
IT **86551-91-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 86551-91-9 CAPLUS
CN 7H-3a,4,7-Methenopyrano[2,3,4-hi]indolizine-5,5(4H)-dicarboxylic acid, 3-cyano-9a,9b-dihydro-2,4,10-triphenyl-, diethyl ester (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

=>

10387318

=> d scan

L3 14 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 6H-2,5,5a-Methenobenzo[g]pyrrolo[1,2,3-cd]benzimidazole-4,4(5H)-dicarboxylic acid, 6-cyano-1,2,10b,10c-tetrahydro-1-methyl-5,11-diphenyl-, diethyl ester, (2α,5α,5aα,6β,10bβ,10cβ,11 S*)- (9CI)
MF C34 H31 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):13

L3 14 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1-Azabicyclo[2.2.1]heptane-2-carboxamide, N-[(4-methoxyphenyl)methyl]- (9CI)
MF C15 H20 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1-Azabicyclo[2.2.1]heptane-2-carboxamide, N-[(4-chlorophenyl)methyl]- (9CI)
MF C14 H17 Cl N2 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1-Azabicyclo[2.2.1]heptane-2-carboxylic acid, ethyl ester (9CI)
MF C9 H15 N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 7H-3,6,6a-Metheno-3H-benzo[f]pyrrolo[3,2,1-ij]quinoline-5-carboxylic acid, 7-cyano-5,6,11b,11c-tetrahydro-6,12-diphenyl-, ethyl ester, (3α,5α,6α,6aα,7β,11bβ,11cβ,12R*)- (9CI)
MF C32 H26 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2,4,4a-Metheno-4aH-7-oxa-1,2a-diazacyclopent[cd]indene-3,3(4H)-dicarboxylic acid, 5-cyano-1,2,7a,7b-tetrahydro-1-methyl-4,6,8-triphenyl-, diethyl ester (9CI)
MF C35 H31 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1-Azabicyclo[2.2.1]heptane-2-carboxamide, N-[(2-chlorophenyl)methyl]- (9CI)
MF C14 H17 Cl N2 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1-Azabicyclo[2.2.1]heptane-2-carboxamide, N-[2-(3,4-dimethoxyphenyl)ethyl]-
(9CI)
MF C17 H24 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1-Azabicyclo[2.2.1]heptane-2-carboxylic acid, 2-(2-nitroethyl)-, ethyl
ester (9CI)
MF C11 H18 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 7H-3a,4,7-Methenopyrano[2,3,4-hi]indolizine-5,5(4H)-dicarboxylic acid,
3-cyano-9a,9b-dihydro-2,4,10-triphenyl-, diethyl ester (9CI)
MF C36 H30 N2 O5

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L3 14 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1-Azabicyclo[2.2.1]heptane-2-carboxamide, N-[(2-methoxyphenyl)methyl]-
(9CI)
MF C15 H20 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1-Azabicyclo[2.2.1]heptane-2-carboxamide, N-[(3-chlorophenyl)methyl]-(9CI)
MF C14 H17 Cl N2 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1-Azabicyclo[2.2.1]heptane-2-carboxamide, N-[2-(4-chlorophenyl)ethyl]-(9CI)
MF C15 H19 Cl N2 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 7H-3,6,6a-Metheno-3H-benzo[f]pyrrolo[3,2,1-ij]quinoline-5,5(6H)-dicarboxylic acid, 7-cyano-11b,11c-dihydro-6,12-diphenyl-, diethyl ester, (3α,6α,6aα,7β,11bβ,11cβ,12R*)- (9CI)
MF C35 H30 N2 O4